Human medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Levodopa/Carbidopa/Entacapone Orion, levodopa,carbidopa,entacapone, Date of authorisation: 23/08/2011, Revision: 15, Status: Authorised
CHMP and Rapporteurs' assessment report template on Similarity Rev. 01.25
Human medicines European public assessment report (EPAR): Skycovion, GBP510, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Masitinib AB Science, masitinib, Date of refusal: 19/12/2024, Status: Refused
Accelerating Clinical Trials in the EU (ACT EU)
Appendix 1: Acceptable intakes established for N-nitrosamines
Human medicines European public assessment report (EPAR): Inlyta, axitinib, Date of authorisation: 03/09/2012, Revision: 17, Status: Authorised
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 25 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 25 February 2025, 11:00 (CET) to 25 February 2025, 11:45 (CET)
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 11 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 February 2025, 11:00 (CET) to 11 February 2025, 11:45 (CET)